Differential effects of EGFR ligands on endocytic sorting of the receptor

Traffic

Volumn 10, Issue 8, 2009, Pages 1115-1127

  Roepstorff, Kirstine ^a   Grandal, Michael Vibo ^a   Henriksen, Lasse ^a   Knudsen, Stine Louise Jeppe ^a   Lerdrup, Mads ^a   Grøvdal, Lene ^a   Willumsen, Berthe Marie ^b   Van Deurs, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amphiregulin; Betacellulin; Endocytic trafficking; Epidermal growth factor; Epidermal growth factor receptor; Epiregulin; Heparin binding EGF like growth factor; Transforming growth factor

Indexed keywords

AMPHIREGULIN; BETACELLULIN; CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; CELL LINE; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; GLYCOPROTEINS; HUMANS; HYDROGEN-ION CONCENTRATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; UBIQUITINATION; VESICULAR TRANSPORT PROTEINS;

EID: 67649889124     PISSN: 13989219     EISSN: 16000854     Source Type: Journal    
DOI: 10.1111/j.1600-0854.2009.00943.x     Document Type: Article

References (38)

1. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp.Cell Res 2003; 284: 2-13.
2. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De LA, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer: An overview. Curr.Drug Targets 2005; 6: 243-257.
3. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 73-80.
4. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001; 61: 6227-6233.
5. Roepstorff K, Grøvdal LM, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: Mechanisms and relevance in cancer. Histochem. Cell Biol 2008; 129: 563-578.
6. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M et al. Cbl-mediated ubiquitylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 2003; 278: 28950-28960.
7. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002; 156: 843-854.
8. Raiborg C, Rusten TE, Stenmark H. Protein sorting into multivesicular endosomes. Curr Opin Cell Biol 2003; 15: 446-455.
9. Ebner R, Derynck R. Epidermal growth factor and transforming growth factor-alpha: Differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 1991; 2: 599-612.
10. Decker SJ. Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem Biophys Res Commun 1990; 166: 615-621.
11. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem 1998; 273: 13819-13827.
12. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008; 1785: 232-265.
13. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000; 20: 91-95.
14. Sorkin A, Krolenko S, Kudrjavtceva N, Lazebnik J, Teslenko L, Soderquist AM, Nikolsky N. Recycling of epidermal growth factor-receptor complexes in A431 cells: Identification of dual pathways. J Cell Biol 1991; 112: 55-63.
15. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 2008; 15: 209-219.
16. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999; 447: 227-231.
17. Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ. Structure and function of human amphiregulin: A member of the epidermal growth factor family. Science 1989; 243: 1074-1076.
18. Oksvold MP, Skarpen E, Lindeman B, Roos N, Huitfeldt HS. Immunocytochemical localization of Shc and activated EGF receptor in early endosomes after EGF stimulation of HeLa cells. J Histochem Cytochem 2000; 48: 21-33.
19. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001; 2: 107-117.
20. Baldys A, Gooz M, Morinelli TA, Lee MH, Raymond JR, Jr., Luttrell LM, Raymond JR, Sr. Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry 2009; 48: 1462-1473.
21. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998; 12: 3663-3674.
22. Jiang X, Huang F, Marusyk A, Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 2003; 14: 858-870.
23. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 2002; 21: 303-313.
24. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999; 4: 1029-1040.
25. Huang F, Sorkin A. Growth factor receptor binding protein 2-mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell 2005; 16: 1268-1281.
26. Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, Pierce JH, Lipkowitz S. cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 1999; 18: 1855-1866.
27. Grøvdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004; 300: 388-395.
28. Alwan HA, van Zoelen EJ, van Leeuwen JE. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 2003; 278: 35781-35790.
29. Hayashi T, Sakamoto S. Radioimmunoassay of human epidermal growth factor-hEGF levels in human body fluids. J Pharmacobiodyn 1988; 11: 146-151.
30. Grau M, Rodriguez C, Soley M, Ramirez I. Relationship between epidermal growth factor in mouse submandibular glands, plasma, and bile: Effects of catecholamines and fasting. Endocrinology 1994; 135: 1854-1862.
31. Beardmore JM, Richards RC. Concentrations of epidermal growth factor in mouse milk throughout lactation. J Endocrinol 1983; 96: 287-292.
32. Gann PH, Chatterton R, Vogelsong K, Grayhack JT, Lee C. Epidermal growth factor-related peptides in human prostatic fluid: Sources of variability in assay results. Prostate 1997; 32: 234-240.
33. Mullin JM. Epithelial barriers, compartmentation, and cancer. Sci.STKE 2004; 2004: E2.
34. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De LA, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer: An overview. Curr Drug Targets 2005; 6: 243-257.
35. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
36. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
37. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, III, Poplin EA, Hidalgo M et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
38. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Janne PA. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008; 14: 6963-6973.